论文信息 - Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease - 字舞流文

Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

S. Vermeire | I. Lawrance | G. D'Haens | A. Maroney | W. Sandborn | B. Feagan | M. Allez | S. D. Lee | R. Fedorak | D. Chang | U. Seidler | A. Heath | B. Feagan | W. Sandborn | C. H. Jurgensen | R. Fedorak | B. G. Feagan | W. J. Sandborn | A. C. Maroney | C. H. Jurgensen | D. J. Chang | S. Vermeire | Geert R. D'Haens | Scott D. Lee | Matthieu Allez | Ursula Seidler | A. C. Maroney | C. H. Jurgensen | D. J. Chang